Biogen Idec Dominant Player In Multiple Sclerosis Market

When a company with a market capitalization of nearly $56 billion is expected to grow annual earnings by 32% in 2013 and 29% in 2014, you know something good is going on. For Biogen Idec (BIIB), the "good" is Tecfidera, its recently approved oral multiple sclerosis (MS) treatment. The drug is widely expected to be a blockbuster for the company. According to some analysts, annual sales of the drug ...

Investing is a subscriber feature. Take a free trial now to get instant access.

Try the Digital + Weekly Print Combo and enjoy the best of both worlds!eIBD is available after market close to give you a head start on the next day's market action. Plus, you get the Weekly Special print edition delivered right to your home or office!

Select market data is provided by Interactive Data Corp. Real Time Services. Price and Volume data is delayed 20 minutes unless otherwise noted, is believed accurate but is not warranted or guaranteed by Interactive Data Corp. Real Time Services and is subject to Interactive Data Corp. Real Time Services terms. All times are Eastern United States. *Reflects real-time index prices.